ZIM Labs Promoter Anwar Daud to Acquire 80,000 Shares from Zulfiquar Kamal
Dr. Anwar Daud, a promoter of Zim Laboratories Limited, will acquire 80,000 shares (0.15%) from fellow promoter Mr. Zulfiquar Kamal. The transaction is an off-market inter-se transfer, exempt under SEBI SAST Regulations. The acquisition can occur on or after June 11, 2026. Post-transaction, Dr. Daud's stake will be 25.05%.
The acquisition involves a small percentage of the total share capital (0.15%) and is between existing promoters. This type of transaction typically has a minimal impact on the company's overall operations or market valuation.
The announcement pertains to an inter-se transfer of shares among existing promoters, which is a routine corporate action and does not inherently indicate a positive or negative shift in the company's performance or outlook.
Zim Laboratories Limited has announced a proposed inter-se transfer of equity shares among its promoters. Dr. Anwar Daud will acquire 80,000 equity shares, representing 0.15% of the company's paid-up equity share capital, from Mr. Zulfiquar Kamal. This transaction is being conducted off-market and qualifies for exemption under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The acquisition is set to take place any time after 4 working days from the date of intimation, which is June 4, 2026, meaning it can occur on or after June 11, 2026. The acquisition price will not exceed the limits provided in the proviso to Regulation 10(1)(a) of the SEBI SAST Regulations. The weighted average market price for the preceding 60 trading days was ₹86.39.
Following this transaction, the shareholding of Dr. Anwar Daud (as part of the promoter group) will increase to 1,63,41,632 shares, constituting 25.05% of the total paid-up equity share capital. The seller, Mr. Zulfiquar Kamal, will continue to hold 33,33,320 shares, representing 24.90% of the total share capital. Both parties confirm compliance with Chapter V of the SEBI (SAST) Regulations.
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.